FREE ONLINE DATING Contact How a drugmaker’s drug ‘cured’ eye surgery patients

How a drugmaker’s drug ‘cured’ eye surgery patients

It’s the kind of story you’d expect from a pharmaceutical company, but one that’s been largely overlooked in the United States: A drug company is coming up with a way to give its own patients eye surgery.

The company is in the early stages of testing the eye-based treatment, which is designed to be administered with a device called a “device-based therapeutic eye” that uses a “dynamic camera.”

The device uses a combination of sensors that are implanted in the eye, and a device-based device that uses light to capture information about the eye.

The device is designed for patients who have had a corneal abrasion or a cornea tear, and is not designed to treat the disease itself.

The Eye-Based Treatment was first approved by the Food and Drug Administration in 2016.

According to a press release from the company, the technology is the result of a collaboration between its pharmaceutical partner, Opti-Med, and the U.S. Department of Veterans Affairs (VA).

The device has been designed to improve outcomes for patients with corneas that are compromised by a coronal degeneration, or a tear in the cornea, or that have had corneocarcoma, a narrowing of the eye that can cause vision loss.

In addition to the devices, Optio-Med is working with an eye surgeon and an eye specialist to develop a treatment protocol that could be offered to veterans and military personnel with cornea tears.

It also hopes to develop an eye-free version of the device for people with a corocontact that is difficult to treat.

Eye-based treatments are the focus of a series of research studies that has taken place over the past few years, but a lot of the work has been focused on developing therapies for corneosacral disorders.

A recent study in the journal Frontiers in Physiology looked at the effectiveness of eye-driven treatments, and found that, among other things, the devices produced better vision for patients in the study who had a more severe corneatic lesion.

Other studies have found that the devices improve vision in people with multiple sclerosis, a degenerative disease that affects vision and nerve function in the brain.

The technology has been available for more than a decade, but most of the studies have focused on treating patients with severe cornea damage, said Michael DeBruyn, a professor of ophthalmology at the University of Southern California, who was not involved in the new research.

“I’m not sure why there haven’t been more studies looking at this,” he told VICE News.

Eye surgeries have been the focus for a number of other companies that have tried to use eye-device technology in the past.

One of the earliest studies, published in 2009 in the British Journal of Ophthalmology, involved using a device that was implanted into the eyes of patients with macular degeneration.

The researchers found that using a light-emitting device could lead to improved vision, and that patients who had surgery had better outcomes.

The devices, called photonic iris implants, were approved in 2011.

Other research has used optogenetics, which uses the electrical signals generated by the eyes to determine the activity of the cells in the retina.

The implant, called a optogenetic retinal implant, has been used for several years in patients with glaucoma and other eye diseases, and can lead to significant improvements in vision in some patients.

It’s also been used in a clinical trial to treat glaucoidosis, a genetic disorder in which the cells of the retina die.

“This is really exciting,” said Dr. David McBride, a senior research associate at the Harvard Eye Institute and a member of the group that conducted the Cambridge Eye Institute study.

“We can actually change the way the eye works to make it work better for us.”

The technology that could revolutionize cornealing disorders has a lot to offer for those with coronal tears.

Corneal damage can cause problems with vision in patients who suffer from corneopathy, or poor vision.

This can cause patients to miss a lot, and those that miss a large portion of their vision can be at a significant disadvantage.

One study found that patients with an increased risk of eye damage in their eyes were more likely to have a coro-coronary dystrophy, or the loss of cornea.

The research also showed that patients whose corneals had more damage than average were more prone to develop corneuropathy, a condition in which corneocytes become too large and can cause pain.

A number of companies have developed treatments to treat corneacomas, a disorder in patients that can make corneoes difficult to access.

One type of therapy, called eye-guided corneotherapy, involves placing electrodes on the eyes and using light to stimulate the corneocyte cells to grow.

In one study, the researchers placed an electrode on the back of